HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2016 13F Holders as of 30 Jun 2016

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
104,978,572
Share change
+2,304,972
Total reported value
$906,530,216
Put/Call ratio
26%
Price per share
$8.63
Number of holders
159
Value change
+$19,234,625
Number of buys
74
Number of sells
66

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2016

As of 30 Jun 2016, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 159 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 104,978,572 shares. The largest 10 holders included Third Security, LLC, IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, BB BIOTECH AG, First Eagle Investment Management, LLC, FMR LLC, BlackRock Fund Advisors, STATE STREET CORP, JPMORGAN CHASE & CO, and BlackRock Institutional Trust Company, N.A.. This page lists 159 institutional shareholders reporting positions in this security for the Q2 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.